Sep 14, 2022 / 07:00PM GMT
Stephen Bersey - HC Wainwright - Analyst
Good day, everyone, and thank you for joining the HC Wainwright 24th Annual Global Investment Hybrid Conference. My name is Stephen Bersey. I'm an equity research associate here at HC Wainwright, and it's my pleasure to introduce Gerri Henwood, President and CEO of Baudax. So now, I'll turn it over to you, Gerri.
Gerri Henwood - Baudax Bio, Inc. - President & CEO
Thanks very much. Thanks for joining this afternoon, hearty souls hanging in here till the end. But we hope we'll make it worth your while.
The lawyers, of course, would like you to look at everything that we have before you make any investment decision. And I've done my duty by saying that before advancing to the next slide.
So this is a summary of where we are as a company right now. ANJESO is our lead commercial product. It is a product that is a non-opioid for treatment of moderate to severe pain, most often associated with use in surgical procedures or associated with other long-lasting pain situations. It's an IV product. We'll talk a
Baudax Bio Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers